An Experimental GLP-1 Pill Delivered Up to 12% Weight Loss in a Mid-Stage Trial

An experimental weight-loss pill helped people lose up to 12% of body weight in a mid-stage trial — the latest sign the GLP-1 class is moving from injections toward once-daily tablets.

Aleniglipron, from Structure Therapeutics, is a small-molecule oral GLP-1 medicine. In a Phase 2b trial of 230 adults (average age 50) across 38 US sites over 36 weeks, weight fell 9.0% at the lowest dose, 10.7% at a middle dose and 12.1% at the highest — versus 0.5% on placebo. Published August 10, 2026 in Nature Medicine.

Why small molecule versus peptide is the whole story

“The difference with aleniglipron is it’s a small molecule,” noted obesity expert Robert Kushner — and that distinction determines almost everything about how such a drug can be supplied.

The established GLP-1 drugs are peptides: chains of amino acids produced biologically, in engineered cells or through complex synthesis. That makes them expensive to manufacture, dependent on specialised capacity that took years to build, and generally requiring refrigeration through distribution and storage.

Peptides are also digested. Taken orally they are broken down before absorption, which is why these drugs are injected — and why the one oral peptide version requires an absorption enhancer, strict fasting instructions, and delivers only a fraction of the dose to circulation.

A small molecule is manufactured by chemical synthesis in conventional facilities, is stable at room temperature, and survives the gut. It is, in supply terms, an ordinary tablet.

What that would change

If oral GLP-1 pills approach injectable results, they could dramatically widen access — easier to make, ship, store and take.

Each of those matters separately. Manufacturing capacity has been the binding constraint on GLP-1 supply, producing years of shortages and a grey market; chemical synthesis scales differently and far more cheaply. Cold-chain distribution limits reach in hot climates and rural areas without reliable refrigeration. And a daily tablet removes the injection barrier that deters a meaningful proportion of eligible patients.

Cost is the most consequential. Cheaper manufacturing does not automatically mean cheaper prices while a drug is on patent — but it changes what is possible, and it changes the economics of eventual generic competition entirely.

How the efficacy compares

12.1% at 36 weeks is a genuine result and should be read against the right comparator.

The leading injectable agents produce more — substantially more at the top end, over longer treatment periods. So this is not equivalence with the best available option.

The relevant question is whether it is enough. Weight loss of 10–12% produces meaningful improvement in blood pressure, glucose control, sleep apnoea and mobility, and it exceeds what any previous generation of oral weight-loss drug achieved. A tablet delivering that at a fraction of the cost and complexity may serve more people in aggregate than a superior injectable that many cannot obtain.

Tolerability

As with other GLP-1 drugs, the main side effects were gastrointestinal — nausea and similar — described as mild to moderate and easing over time. About 10.4% of participants stopped treatment, and no drug-induced liver injury was reported.

The liver point is not routine reassurance. An earlier oral small-molecule GLP-1 candidate from another developer was discontinued over liver signals, which raised a question about whether the chemical class carried a specific hepatic risk. A clean liver profile here addresses that directly.

A 10.4% discontinuation rate is comparable to injectable GLP-1s, suggesting the oral route does not worsen the gastrointestinal problem — which was not guaranteed, since a drug absorbed through the gut acts on it more directly.

What Phase 3 will test

Structure plans a Phase 3 with an adjusted dose-escalation schedule to improve tolerability.

That is the standard approach in this class: starting low and increasing gradually lets the gut adapt, reducing nausea and dropout. Getting the schedule right frequently determines how much of the theoretical dose patients actually tolerate, and therefore how much weight they lose in practice rather than in principle.

The oral GLP-1 race

Aleniglipron is one entrant in a contest that has become one of the most watched in the industry, and the competitive shape matters for how the result should be read.

The largest incumbents in injectable GLP-1 are both pursuing oral versions, one through a peptide reformulated for oral absorption and others through small molecules of their own. Several smaller companies are developing candidates, and at least one earlier small-molecule programme was discontinued over liver safety.

What distinguishes them commercially will probably not be efficacy alone. Manufacturing cost, dosing convenience — whether a tablet must be taken fasting and how strictly — tolerability at effective doses, and the ability to supply at genuine scale will all bear on which reaches most patients.

The last of those may dominate. The injectable market has been supply-constrained for years, and a company able to manufacture an oral small molecule in conventional chemical plants could reach a population the injectables have never been able to serve — which is a different competitive advantage from being marginally more effective.

These are mid-stage results in 230 people over 36 weeks. Larger and longer trials will decide the drug’s place — particularly whether the effect is maintained, since weight regain after stopping is near-universal across this class. Clinical research news, not medical advice.